Secukinumab reduces signs and symptoms of active ankylosing spondylitis: Results from a 16-week, randomized placebo-controlled phase 3 trial

Authors
Category Primary study
ConferenceJournal of Clinical Rheumatology
Year 2016
This article has no abstract
Epistemonikos ID: 2556aba27afb44c988d6d76396318446e89f9673
First added on: Apr 29, 2026